1. Home
  2. IMMX vs MATH Comparison

IMMX vs MATH Comparison

Compare IMMX & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMX
  • MATH
  • Stock Information
  • Founded
  • IMMX 2014
  • MATH 2015
  • Country
  • IMMX United States
  • MATH Hong Kong
  • Employees
  • IMMX N/A
  • MATH N/A
  • Industry
  • IMMX Medicinal Chemicals and Botanical Products
  • MATH Finance/Investors Services
  • Sector
  • IMMX Health Care
  • MATH Finance
  • Exchange
  • IMMX Nasdaq
  • MATH Nasdaq
  • Market Cap
  • IMMX 61.1M
  • MATH 60.8M
  • IPO Year
  • IMMX 2021
  • MATH N/A
  • Fundamental
  • Price
  • IMMX $2.65
  • MATH $3.21
  • Analyst Decision
  • IMMX Strong Buy
  • MATH
  • Analyst Count
  • IMMX 1
  • MATH 0
  • Target Price
  • IMMX $7.00
  • MATH N/A
  • AVG Volume (30 Days)
  • IMMX 220.7K
  • MATH 234.8K
  • Earning Date
  • IMMX 08-11-2025
  • MATH 08-26-2025
  • Dividend Yield
  • IMMX N/A
  • MATH N/A
  • EPS Growth
  • IMMX N/A
  • MATH N/A
  • EPS
  • IMMX N/A
  • MATH 0.41
  • Revenue
  • IMMX N/A
  • MATH $44,567,257.00
  • Revenue This Year
  • IMMX N/A
  • MATH N/A
  • Revenue Next Year
  • IMMX N/A
  • MATH N/A
  • P/E Ratio
  • IMMX N/A
  • MATH $7.83
  • Revenue Growth
  • IMMX N/A
  • MATH 165.86
  • 52 Week Low
  • IMMX $1.26
  • MATH $0.80
  • 52 Week High
  • IMMX $3.20
  • MATH $4.17
  • Technical
  • Relative Strength Index (RSI)
  • IMMX 49.64
  • MATH 46.10
  • Support Level
  • IMMX $2.63
  • MATH $3.03
  • Resistance Level
  • IMMX $3.20
  • MATH $4.06
  • Average True Range (ATR)
  • IMMX 0.22
  • MATH 0.44
  • MACD
  • IMMX -0.04
  • MATH -0.04
  • Stochastic Oscillator
  • IMMX 3.51
  • MATH 17.54

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.

Share on Social Networks: